文献速递组学、生物样本库与精准医学基础与转化研究

弥漫大B细胞淋巴瘤的遗传学与发病机制

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
PubMed 文献 · N Engl J Med · 2018-01-01

该研究对574例DLBCL活检样本进行外显子组和转录组测序、基于芯片的DNA拷贝数分析及372个基因的靶向扩增子重测序,以识别反复出现的基因异常,并开发算法基于基因改变共现发现遗传亚型。研究识别出MCD、BN2、N1和EZB四个主要遗传亚型,各亚型在基因表达特征和对免疫化疗的反应上存在差异,BN2和EZB亚型生存较好,MCD和N1亚型结局较差。

要点

  • 基于基因改变共现识别出DLBCL四个遗传亚型:MCD、BN2、N1和EZB。
  • BN2和EZB亚型生存较好,MCD和N1亚型结局较差。
  • MCD和BN2亚型依赖慢性活跃B细胞受体信号,可能适合靶向抑制。

核心结论

  • 研究揭示了DLBCL具有不同基因型、表观遗传和临床特征的遗传亚型,为DLBCL精准医学策略提供了潜在分类学基础。

研究设计与样本

  • 研究纳入574例DLBCL活检样本,采用外显子组和转录组测序、基于芯片的DNA拷贝数分析及372个基因的靶向扩增子重测序识别反复基因异常。
  • 开发并实施算法,基于基因改变共现发现遗传亚型。

主要发现

  • 识别出四个主要遗传亚型:MCD(基于MYD88L265P和CD79B突变共现)、BN2(基于BCL6融合和NOTCH2突变)、N1(基于NOTCH1突变)、EZB(基于EZH2突变和BCL2易位)。
  • 每个遗传亚型由多个基因的遗传异常与其他DLBCL区分。
  • 各亚型在基因表达特征和对免疫化疗反应上存在表型差异,BN2和EZB亚型生存较好,MCD和N1亚型结局较差。
  • 遗传通路分析提示MCD和BN2 DLBCL依赖「慢性活跃」B细胞受体信号,该信号可被治疗性抑制。

临床怎么用

  • 基于基因共现的遗传亚型分类可能辅助DLBCL精准医学策略的制定。
  • MCD和BN2亚型的慢性活跃B细胞受体信号提示潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell-like [ABC], germinal-center B-cell-like [GCB], and unclassified) according to cell of origin that are associated with a differential response to chemotherapy and targeted agents. We sought to extend these findings by identifying genetic subtypes of DLBCL based on shared genomic abnormalities and to uncover therapeutic vulnerabilities based on tumor genetics. METHODS: We studied 574 DLBCL biopsy samples using exome and transcriptome sequencing, array-based DNA copy-number analysis, and targeted amplicon resequencing of 372 genes to identify genes with recurrent aberrations. We developed and implemented an algorithm to discover genetic subtypes based on the co-occurrence of genetic alterations. RESULTS: We identified four prominent genetic subtypes in DLBCL, termed MCD (based on the co-occurrence of MYD88L265P and CD79B mutations), BN2 (based on BCL6 fusions and NOTCH2 mutations), N1 (based on NOTCH1 mutations), and EZB (based on EZH2 mutations and BCL2 translocations). Genetic aberrations in multiple genes distinguished each genetic subtype from other DLBCLs. These subtypes differed phenotypically, as judged by differences in gene-expression signatures and responses to immunochemotherapy, with favorable survival in the BN2 and EZB subtypes and inferior outcomes in the MCD and N1 subtypes. Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on "chronic active" B-cell receptor signaling that is amenable to therapeutic inhibition. CONCLUSIONS: We uncovered genetic subtypes of DLBCL with distinct genotypic, epigenetic, and clinical characteristics, providing a potential nosology for precision-medicine strategies in DLBCL. (Funded by the Intramural Research Program of the National Institutes of Health and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018. PMID: 29641966. doi:10.1056/NEJMoa1801445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。